India Pharma Outlook Team | Thursday, 15 January 2026
Dr. Reddy's Laboratories Ltd. has announced the launch of its over-the-counter (OTC) Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% in the U.S. market.
This is a generic product of the Extra Strength Pataday Once-Daily Relief that is certified by the U.S Food and Drug Administration (USFDA).
The eye drop is meant to offer a short-term relief of itchy eyes because of pollen, ragweed, grass, and animal dander allergens.
Also Read: Advancing Interventional Radiology in India Through Collaboration
The CEO of North America Generics at Dr. Reddy laboratories, Milan Kalawadia said, this is an addition to our existing portfolio in the OTC eye-care sector that already includes Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1%. He stressed that this first in the market introduction underscores the effective capacity of the company in providing store-level alternatives of well known OTC brands in the American market.
The introduction comes after the Pataday brand experienced high sales approximately 69.9 million US dollars in 52 weeks ending on December 27, 2025 according to NIQ data, and the Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7 percent is offered in a 2.5 mL bottle, which contributes to the affordability of the brand to its customers in need of help in their eyes due to allergies.
The step enhances the role of Dr. Reddy in the competitive U.S. OTC eye-care market and strengthens its partnership with retailers.
.jpg)
.jpg)
